oncology
ASCO 2011: news from the front line against cancer
July 18, 2011Research and Development ASCO, Cancer, oncology
Pharmafocus presents selected highlights from the American Society of Clinical Oncology’s annual meeting in Chicago, beginning with non-small cell lung …
Lilly prepares late-stage pipeline boost
July 1, 2011Research and Development, Sales and Marketing autoimmune diseases, diabetes, lilly, neuroscience, oncology
Eli Lilly has highlighted diabetes, oncology, autoimmune diseases and neuroscience as key therapy areas within its growth strategy. Within these …
BMS and Roche to team up in melanoma
June 3, 2011Sales and Marketing BMS, Roche, melanoma, oncology
Bristol-Myers Squibb and Roche are to use two of their drugs in an exploratory phase I/II study a bid to …
Bayer-helmed oncology biomarker project launched
March 14, 2011Manufacturing and Production, Research and Development AstraZeneca, Bayer, Janssen, Max Planck Institute, Merck, OncoTrack, Pfizer, Roche, biomarkers, oncology
A project to develop the next generation of oncology biomarkers has been launched in Berlin. The pharma industry and European …
Glioblastoma vaccine enters phase II
February 24, 2011Research and Development Cancer, GBM, ImmunoCellular Therapeutics, oncology
The first patient has been enrolled in a phase II trial of ICT-107, a cancer vaccine candidate for the treatment …
Roche highlights R&D promise after setbacks
December 9, 2010Research and Development MS, Roche, oncology, personalised medicine, schizophrenia
Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …
Pharma unprepared for personalised oncology
November 29, 2010Research and Development, Sales and Marketing Cancer, ESMO, ESMO Cancer Biology for Clinicians Symposium, oncology, personalised medicine
The new era of personalised cancer care requires different thinking from pharma companies, according to experts at the ESMO symposium. …
Celgene completes Abraxis takeover
October 15, 2010Research and Development, Sales and Marketing Abraxane, Abraxis, Celgene, mergers and acquisitions, oncology
Celgene has completed its acquisition of Abraxis BioScience for cash and stock totalling $2.9 billion. The takeover gives the cancer …
Cancer Research UK and Merck KGaA to co-develop leukaemia candidate
January 4, 2010Research and Development Merck Serono, leukaemia, oncology
Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialisation arm, are to undertake a phase I …
